Local Regulatory Partner for EU & US
Facilitating Safe and Effective Pharmaceuticals through Local Regulatory Collaboration
We offer regulatory expertise in regulatory compliance for safe & effective pharmaceuticals
In the pharmaceutical sector,local health authorities generally collaborate with pharmaceutical companies to supervise and approve medications and medical equipment for efficacy and safety. This process involves examining clinical trial data, monitoring post-approval safety, and inspecting manufacturing facilities. Several important health agencies include the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), and the US Food and Drug Administration (FDA). These organisations are essential in maintaining public health because they establish guidelines and implement rules pertaining to the creation and dispensing of pharmaceuticals.
Local Regulatory Partner for EU & US
- Overview
It takes in-depth knowledge and experience to navigate the intricate regulatory environments of the US and the EU. Our team has extensive experience working with various health agencies like the FDA, EMA, and Health Canada. We understand the importance of building strong relationships with these authorities and can help navigate the complex regulatory environment to achieve your goals.
Here at Zenovel, we provide committed regulatory collaboration services to support the approval and success of your pharmaceutical products in these vital regions.
- Our Services
- Why Choose Zenovel ?
- Expertise
Experienced professionals with vast knowledge of FDA and EU regulations
- Efficiency
Streamline process, Reduce time to market, Minimize delays
- Compliance
Mitigate risk, Enhance approval success rates
- Local Presence
Acts as a Local Regulatory Partner for EU & US, Offer insights
People Also Ask (FAQs)
A local regulatory partner for the EU and US helps pharmaceutical, biotech, and medical device companies navigate regulatory requirements set by authorities such as the FDA and EMA. These partners provide expertise in regulatory strategy, dossier preparation, submissions, and communication with regulatory agencies to ensure successful product approvals.
Companies need a local regulatory partner to ensure compliance with region-specific regulatory frameworks, reduce submission errors, and streamline approval timelines. Expertise in FDA and EU regulations helps companies efficiently manage submissions and stay aligned with evolving guidelines. Zenovel supports this role by providing region-specific regulatory expertise, guiding companies through complex requirements, and ensuring accurate, compliant, and timely submissions across global markets.
A local regulatory partner typically provides services such as regulatory strategy development, dossier preparation (CTD/eCTD), regulatory submissions, lifecycle management, and communication with health authorities. These services support pharmaceutical companies in achieving faster regulatory approvals and smoother market entry.
Zenovel supports pharmaceutical and biotech companies by providing regulatory consulting, submission management, and documentation support tailored to EU and US requirements. Their team helps ensure that regulatory dossiers meet global standards and align with guidelines from agencies like the FDA and EMA.
Working with an experienced regulatory partner helps companies avoid common submission mistakes, prepare accurate regulatory documentation, and follow the correct regulatory pathway. This reduces regulatory queries, improves submission quality, and helps accelerate product approvals in highly regulated markets like the EU and US.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
